View the complimentary infographic below to see examples of lost opportunities for Merck Serono's Rebif, Mylan's generic glatiramer acetate, Sanofi Genzyme's Aubagio, and Biogen's Tysabri and which brands increased their WIN RATIO as a result and why they competed successfully.
While dermatologists continue to report high satisfaction with the first FDA approved biologic, there is still a large unmet need for new pharmacologic treatments for atopic dermatitis. Sanofi/Regeneron’s Dupixent continues to exceed expectations and current users remain extremely satisfied with the first biologic approved to treat moderate-to-severe atopic dermatitis.
A survey of 202 nephrologists fielded in June 2018 provides the latest trends in the CKD-ND and dialysis settings. See complimentary highlights from the Q2 2018 wave of RealTime Dynamix™: Renal Anemia US below.
How similar are real world patients with SLE to those studied in clinical trials? Click the complimentary infographic for an example of the eligibility of audited patients based on a current clinical trial’s inclusion criteria.
The US dermatology market has undergone rapid change over the past several years, with the introduction of six new biologics in psoriasis alone—five of which are biologics with alternate mechanisms of action (MOA).